Ayman Wahbeh

Prof. Dr. Ayman Wahbeh

Internal Medicine and Nephrology, University of Jordan, Amman, Al ‘Āşimah, Jordan
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
AYA. Yango
A. Yango
PMP. Morrissey
P. Morrissey
RGR. Gohh
R. Gohh
AWAyman Wahbeh
Ayman Wahbeh
AMA. Monaco
A. Monaco

22 January 2009 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
SDSaid S. Dahbour
Said S. Dahbour
AWAyman Wahbeh
Ayman Wahbeh
MHMohammad Z. Hamdan
Mohammad Z. Hamdan

15 January 2008 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
FBFaris Bakri
Faris Bakri
AWAyman Wahbeh
Ayman Wahbeh
AMAzmi Mahafzah
Azmi Mahafzah
MTMusleh Tarawneh
Musleh Tarawneh

1 May 2009
Verified
Journal Article
Closed access
AWAyman Wahbeh
Ayman Wahbeh
MEMohammad H Ewais
Mohammad H Ewais
MEMahamed E Elsharif
Mahamed E Elsharif

16 April 2025 in Health Science Reports
Verified
Journal Article
Open access
HAHussein Alhawari
Hussein Alhawari
YJYazun Jarrar
Yazun Jarrar
MZMalek Zihlif
Malek Zihlif
AWAyman Wahbeh
Ayman Wahbeh
SASameeha Alshelleh
Sameeha Alshelleh
DADalia Abdelrazaq
Dalia Abdelrazaq
Background: Valsartan, an angiotensin receptor antagonist widely used in hypertension and heart failure management, exhibits noticeable interindividual variation in response among hypertensive patients at the University of Jordan Hospital. The angiotensinogen (AGT) gene variant M235T, a functional genetic variant, influences the renin‐angiotensin system.Aims: This study aims to explore interindividual variations in the valsartan response, considering genetics, particularly the AGT M235T variant, and other nongenetic factors.Methods: This cohort study involved 95 unrelated Arabic Jordanians diagnosed with essential hypertension. Systolic (SBP) and diastolic blood pressure (DBP) measurements were taken at the initiation of 160 mg valsartan and after 1 month of treatment, assessing the valsartan response for each patient. Genetic analysis of AGT M235T was done using the polymerase chain reaction‐restriction fragment length polymorphism genotyping method. Anthropometric data were collected from University of Jordan Hospital computer records.Results: Valsartan response assessment revealed diverse individual responses, the response to valsartan varied, with SBP reductions from < 10 to > 70 mmHg and DBP from < 2 to 30 mmHg. Patients with homozygous AGT M235T genotypes showed a less significant response (p < 0.05) to valsartan than heterozygous and reference genotypes. Additionally, results indicated a positive correlation of age (p = 0.03) and a negative correlation of height (p = 0.02–0.04) with the valsartan response. Regression analysis demonstrated that the patients' sex significantly influenced the valsartan response (p < 0.05).Conclusions: This study identifies the AGT M235T genotype as a potential genetic contributor to variability in the valsartan response. Associations with age, height, and sex underscore the importance of considering genetic and demographic factors in tailoring valsartan therapy, for advancing personalized hypertension management.

3 April 2012 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
NBNailya Bulatova
Nailya Bulatova
AYAl-Motassem Yousef
Al-Motassem Yousef
HQHisham Qusa
Hisham Qusa
GKGhada Al Khayat
Ghada Al Khayat
WAWadad Ailabouni
Wadad Ailabouni
MAMuhammad Al-Ulemat
Muhammad Al-Ulemat